Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
Clinical trial NCT05356195 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05356195
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-03
- Primary completion
- 2027-11-14
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.